ALNYLAM PHARMACEUTICALS, INC. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Alnylam Pharmaceuticals, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2018 to Q2 2024.
  • Alnylam Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $198M, a 5.03% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $198M -$10.5M -5.03% Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $195M -$19.6M -9.11% Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $200M -$15.4M -7.16% Dec 31, 2023 10-Q 2024-08-01
Q3 2023 $203M -$15.3M -7% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $209M -$15.1M -6.75% Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $215M -$13.7M -6% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $215M -$16.5M -7.14% Dec 31, 2022 10-K 2024-02-15
Q3 2022 $219M -$17.1M -7.23% Sep 30, 2022 10-Q 2022-10-27
Q2 2022 $224M -$14.2M -5.95% Jun 30, 2022 10-Q 2022-07-28
Q1 2022 $229M -$8.44M -3.56% Mar 31, 2022 10-Q 2022-04-28
Q4 2021 $232M -$9.81M -4.06% Dec 31, 2021 10-K 2023-02-23
Q3 2021 $236M -$9.38M -3.83% Sep 30, 2021 10-Q 2021-10-28
Q2 2021 $238M +$8.42M +3.66% Jun 30, 2021 10-Q 2021-08-03
Q1 2021 $237M +$15.9M +7.2% Mar 31, 2021 10-Q 2021-04-29
Q4 2020 $241M +$20.3M +9.17% Dec 31, 2020 10-K 2022-02-10
Q3 2020 $245M +$21.8M +9.75% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $230M +$3.32M +1.47% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $221M -$5.13M -2.27% Mar 31, 2020 10-Q 2020-05-06
Q4 2019 $221M -$8.8M -3.83% Dec 31, 2019 10-K 2021-02-11
Q3 2019 $223M Sep 30, 2019 10-Q 2019-10-31
Q2 2019 $226M Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $226M Mar 31, 2019 10-Q 2019-05-02
Q4 2018 $230M Jan 1, 2019 10-Q 2019-10-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.